**Introducing the TrypanoGEN biobank: A valuable resource for the elimination of human African trypanosomiasis**

Hamidou Ilboudo1, Harry Noyes2, Julius Mulindwa3, Magambo Phillip Kimuda3,4, Mathurin Koffi5, Justin Windingoudi Kaboré1, Ahouty Bernadin5, Dieudonné Mumba6, Olivier Fataki6, Gustave Simo7, Elvis Ofon7, John Enyaru3, John Chisi8, Kelita Kamoto8, Martin Simuunza9, Vincent P. Alibu3, Veerle Lejon10, Vincent Jamonneau10.11, Annette Macleod12, Mamadou Camara13, Bruno Bucheton10.13,Christiane Herz-Fowler2, Issa Sidibe1, Enock Matovu3\* for the TrypanoGEN Research Group as members of The H3Africa Consortium

1Centre International de Recherche-Développement sur l’Elevage en zone Subhumide (CIRDES), Bobo-Dioulasso, Burkina Faso; 2Centre for Genomic Research, University of Liverpool, UK; 3Makerere University, Kampala, Uganda; 4Research Unit in Bioinformatics (RUBi), Department of Biochemistry and Microbiology, Rhodes University, South Africa; 5Université Jean Lorougnon Guédé (UJLoG), Daloa, Côte d’Ivoire; 6Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of Congo; 7Faculty of Science, University of Dschang, Cameroon; 8University of Malawi, College of Medicine, Department of Basic Medical Sciences, Blantyre, Malawi; 9Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia; 10Institut de Recherche pour le Développement (IRD), IRD-CIRAD 177, Montpellier, France; 11Institut Pierre Richet, Bouaké, Côte d’Ivoire, 12Wellcome Trust Centre for Molecular Parasitology, University Place, Glasgow, UK; 13Programme National de Lutte contre la Trypanosomose Humaine Africaine, Conakry, Guinea,

\* Email: matovue04@yahoo.com

**Background**

Human African trypanosomiasis (HAT) or sleeping sickness is a disease caused by two sub-species of the protozoan parasite, *Trypanosoma brucei* (*T. b*)*; T. b. gambiense* and *T. b. rhodesiense. T. b. gambiense* causes the chronic form of sleeping sickness in West and Central Africa and it is responsible for 98% of all reported cases [[1](#_ENREF_1)]. *T. b. rhodesiense* causes an acute, rapidly progressive infection in Eastern and Southern Africa. Over the last decade control measures have reduced HAT incidence to less than 3,000 reported cases in 2015, the lowest level in 75 years [[2](#_ENREF_2)]. The target of the World Health Organization (WHO) is the elimination of the disease as a public health problem by 2020 and interruption of its transmission by 2030 [[1](#_ENREF_1)].

HAT has been considered as an invariably fatal disease. However, recent studies argue that this is not the case [[3-5](#_ENREF_3)]. Infection by *T. b. gambiense* can result in a wide range of clinical outcomes in its human host [[3-5](#_ENREF_3)]. This has been illustrated by the descriptions of self-cure in HAT patients refusing treatment in Ivory Coast [[6](#_ENREF_6)] and the report of a patient who developed sleeping sickness in the UK 29 years after he last left an endemic area [[7](#_ENREF_7)]. Furthermore, individuals with an elevated response to the Card Agglutination Test for Trypanosomiasis (CATT) and positive to the specific *T .b. gambiense* immune trypanolysis test, but who remain negative to available microscopic parasitological tests for more than two years, have been reported in West Africa and are believed to harbor latent infections [[8](#_ENREF_8),[9](#_ENREF_9)]. These observations suggest that individuals infected with *T. b. gambiense* may exhibit variable degrees of susceptibility and some may be able to control the infection over long periods of time, as has also been demonstrated for African Animal Trypanosomiasis (AAT) caused by *T. congolense* [[10](#_ENREF_10),[11](#_ENREF_11)].

The TrypanoGEN network is composed of researchers from Burkina Faso, Cameroon, Côte d’Ivoire, Guinea, Democratic Republic of Congo (DRC), Malawi, Uganda, Zambia, France, United Kingdom and Belgium and is aimed at understanding the genetic basis of human susceptibility to trypanosomiasis. The TrypanoGEN network is a member of the Human Heredity and Health in Africa (H3Africa [www.h3africa.org](http://www.h3africa.org))) consortium which is an initiative funded and supported by the Wellcome Trust (UK) and the National Institutes of Health (USA). Members of the H3Africa Consortium are undertaking genome wide association studies (GWAS) on a wide range of communicable and non-communicable diseases. H3Africa members are committed to making all specimens and data available to other researchers [[12](#_ENREF_12)].

The objectives of the TrypanoGEN network are to identify the human genetic determinants of disease susceptibility/resistance in different African populations and to determine if these are shared for the two diseases caused by the different trypanosome sub-species. To address these scientific questions, the TrypanoGEN project has created a biobank of specimens with standardized parasitological and clinical data. HAT is a disease of rural Africa, often in areas with limited health resources and impoverished populations. The diagnosis of trypanosomiasis and particularly of sub-clinical cases requires multiple tests in both the field and the laboratory. Large specimen collections from cases and individuals with latent infections require large surveys in areas that are remote from research laboratories. Both these factors make it hard to obtain large numbers of well phenotyped specimens. To date, all the genetic association studies on the susceptibility in HAT have been performed on limited numbers of specimens sampled in single countries [[13-16](#_ENREF_13)]. Thus, the TrypanoGEN biobank is an important resource to enable the first genome wide association study (GWAS) of HAT using a large and well-characterised specimen collection originating from different populations. A GWAS will make it possible to identify genetic determinants of susceptibility/resistance and to validate hypotheses developed in the laboratory and facilitate the development or evaluation of new diagnostic tests.

In this article we described the TrypanoGEN Network biobank for human African trypanosomiasis where all specimens used in our research are archived and made available to other researchers. Another Biobank of specimens from HAT patients and endemic controls has been established previously by the WHO but this is exclusively for the development of HAT diagnostic tests and specimens are not available for genetic research [[17](#_ENREF_17)].

**What Are the Characteristics and Requirements of the HAT Biobank?**

**What Ethical approval was obtained?**

Ethical approval was provided by the national ethics councils of each of the TrypanoGEN participating countries: Cameroon (2013/364/L/CNERSH/SP), Democratic Republic of Congo (No 1/2013), Guinea (1-22/04/2013), Cote d’Ivoîre (2014/No 38/MSLS/CNER-dkn), Malawi (1213), Uganda (HS 1344), and Zambia (011-09-13). Information (in English or French and several local languages) was provided to the participants through community engagement with potential participants and community leaders at every field visit. This information included the scientific objectives of the TrypanoGEN network. The participants were guided through the consent forms and written consent was obtained to collect biological specimens. This consent represents a broad consent that allows for genomic investigations as part of the TrypanoGEN network. Genetic studies on HAT by other researchers are allowed but require approval from the Institutional Review Boards of the country that supplied the specimens.

**From whom were specimens collected?**

Study participants were classified into three groups depending on the serological and parasitological results.:

* Cases, defined as individuals with trypanosomes detected in either lymph node aspirate, blood, or cerebrospinal (CSF) by microscopy, after concentrating parasites if necessary [[18-21](#_ENREF_18)]
* Individuals with latent infections, with positive CATT [[22](#_ENREF_22)] and trypanolysis test presults [[23](#_ENREF_23)] in whom no trypanosomes were detected by microscopy for at least two years..
* Controls, defined as individuals living in an endemic area who were CATT and trypanolysis negative, with no signs and symptoms suggestive of HAT and without evidence of previous HAT infection. The controls had similar age and gender distributions as the cases (Fig 1).

Fig 1. Age frequencies of cases and controls. Many participants did not know their age and approximate ages were assigned to many subjects leading to large spikes of numbers at 30,40,50 and 60 years with minor spikes at five year intervals. These spikes were smoothed using a moving window average over ten years. The mean ages of *T. b. gambiense* and *T. b. rhodesiense* cases and controls were 36 and the 42 respectively. The age distributions were similar except that the *T. b. rhodesiense* subjects ages were shifted to the right.

In total, the TrypanoGEN biobank currently includes 1345 cases, 179 individuals with latent infections and 1777 controls (Table 1).

**Table 1:** Number of individuals by country with test results that meet the criteria for specimen classification

|  |  |  |  |
| --- | --- | --- | --- |
| Country | Cases   | Latent Infections | Controls |
| ***T. b. gambiense*** |   |   |   |
| Guinea | 346 | 89 | 193 |
| Ivory Coast | 123 | 18 | 271 |
| DRC | 213 | 72 | 282 |
| Cameroon | 56 | - | 160 |
| Uganda | 157 | - | 227 |
| ***T. b. rhodesiense*** |  |  |  |
| Uganda | 245 | - | 372 |
| Malawi | 162 | - | 200 |
| Zambia | 39 | - | 62 |
| Total | 1345 | 179 | 1777 |

**How were specimens collected?**

Specimens for the Biobank were generally collected during field surveys in collaboration with national control programs in three different ways:

* Previously archived specimens: existing collections of previously archived specimens were centralized into their respective network node. For previously archived specimens, all individuals were revisited to obtain consent.
* Retrospectively collected specimens: study sites were revisited to consent and resample previously diagnosed and treated patients and individuals with latent infections.
* Prospectively collected specimens: HAT cases before treatment and individuals with latent infections were identified as part of active surveillance surveys performed by the spoke teams in collaboration with their respective National Control Programs (NCP).

Whole blood, plasma and buffy coat (BC) were collected from each study participant following good clinical practice principles. The specimens were frozen in the field at -20°C before final storage at -80°C.

Epidemiological and laboratory data were recorded and linked to biological specimens (Table 2). Plasma was used to perform the trypanolysis test. Blood or BC was used for DNA extractions using the Whole Blood Midikit from Qiagen. DNA was quantified by fluorometric Qubit assay (Invitrogen) or Nanodrop spectrophotometer.

**Table 2**: Metadata associated with each specimen in the database

|  |  |
| --- | --- |
| Epidemiological Data | Laboratory data |
| ID | Trypanolysis result |
| Country | Parasitological result |
| Focus |  |
| Village |  |
| Sex |  |
| Age |  |
| Language |  |

**Where were specimens collected and stored?**

The biobank stores plasma and DNA from blood in three hubs that are responsible for specimen management and associated data, including reception, control, processing, storage, and subsequent distribution to end-users. Shipment from intermediate national storage to the central hubs was by express courier on dry ice.

A map of the TrypanoGEN network is given in Fig 2. Specimens are held at the following locations:

* the College of Veterinary Medicine, Animal Resources & Bio-security (COVAB), Makerere University, Kampala, Uganda. This location preserves specimens from the *T. b. gambiense* endemic districts of Northwestern and the *T. b. rhodesiense* endemic districts of Eastern Uganda as well as from the Rumphi and Nkhotakota foci in Malawi and multiple districts of Zambia.
* Centre International de Recherche-Développement sur l’Elevage en zone Subhumide (CIRDES), Burkina Faso, which holds specimens from Forécariah, Dubréka and Boffa foci collected by the National Control Programme of Guinea and from Bonon and Sinfra foci in Côte d’Ivoire collected by the Université Jean Lorougnon Guédé, Daloa, Côte d’Ivoire;
* Institut National de Recherche Biomedicale (INRB), Kinshasa, Democratic Republic of the Congo, holds specimens from Bandundu, DRC and from the Campo and Bipindi foci in Cameroon collected by the Faculty of Science, University of Dschang, Cameroon.

Fig 2. Map showing countries from which samples were collected and the proportion of each type of subject in the collection. Stars indicate locations of Biobank hubs.

**What metadata are associated with specimens?**

Metadata associated with each specimen are shown in Table 2. Phenotyping was focused solely on HAT, no screening was done for other infections. 298 DNA specimens from six countries have been subject to whole genome sequencing to 10X coverage. Cases, latent infections individuals and Controls will be genotyped using the H3Africa 2.5 million SNP chip genotyping assay [[12](#_ENREF_12)]. The sequence data and SNP chip data will be associated with the subjects and made freely available, under the standard H3Africa data release policy, one year after data collection is completed. Information on the policies for specimens and data sharing and guidelines are accessible through the H3Africa website ([www.h3africa.org](http://www.h3africa.org)) [[12](#_ENREF_12)].

**How can users access to the TrypanoGEN biobank?**

The specimens are accessible to the members of the network for further research on HAT after review of applications by the sample access committee and subject to a Material Transfer Agreement. Interested researchers from outside the TrypanoGEN network should request access to the Biobank through the PIs of the three hubs who will refer requests to the TrypanoGEN sample access committee so that they can find if there are specimens available that meet the needs. Contact details of the PIs are available from the project website: www.trypanogen.net.

The TrypanoGEN biobank database is web-accessible and allows the user to browse and filter TrypanoGEN subjects to identify sets of subjects that might be appropriate for a particular study. Access to the database is available on request to the PIs of the hubs. Access will be provided to researchers to evaluate the utility of the specimens for their purpose and make specific requests for specimen sets.

Learning Points

* The rapidly declining cost of genetic assays means that specimen collection is now the most, expensive, laborious and time consuming part of genetic research. The Biobank will share this valuable resource to facilitate studies that would not otherwise be possible.
* The H3Africa consortium members are setting up Biobanks for specimens associated with a wide range of conditions. This is an opportune moment to set up collaborations with research questions cutting across regions.
* Experimental reproducibility is a hot current topic [[24](#_ENREF_24)]. The availability of a large standard set of specimens from multiple populations will allow researchers to undertake well powered experiments that can reveal both population specific and Africa wide associations with trypanosomiasis that can be tested for reproducibility by other researchers.

**Acknowledgements:** We thank subjects who generously donated their specimens and the large numbers of field workers from the participating countries for their dedication in collecting and processing these specimens.

**References**

1. WHO (2013) Control and surveillance of human African trypanosomiasis. WHO Technical Report Series 984 Geneva.

2. WHO (2016) Lowest caseload recorded as the world prepares to defeat sleeping sickness. <http://wwwwhoint/neglected_diseases/news/HAT_lowest_caseload_recorded/en/>.

3. Bucheton B, MacLeod A, Jamonneau V (2011) Human host determinants influencing the outcome of Trypanosoma brucei gambiense infections. Parasite Immunol 33: 438-447.

4. Checchi F, Filipe JA, Barrett MP, Chandramohan D (2008) The natural progression of *Gambiense* sleeping sickness: what is the evidence? PLoS Negl Trop Dis 2: e303.

5. Sternberg JM, Maclean L (2010) A spectrum of disease in Human African trypanosomiasis: the host and parasite genetics of virulence. Parasitology 137: 2007-2015.

6. Jamonneau V, Ilboudo H, Kabore J, Kaba D, Koffi M, et al. (2012) Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis 6: e1691.

7. Sudarshi D, Lawrence S, Pickrell WO, Eligar V, Walters R, et al. (2014) Human African trypanosomiasis presenting at least 29 years after infection--what can this teach us about the pathogenesis and control of this neglected tropical disease? PLoS Negl Trop Dis 8: e3349.

8. Garcia A, Jamonneau V, Magnus E, Laveissiere C, Lejon V, et al. (2000) Follow-up of Card Agglutination Trypanosomiasis Test (CATT) positive but apparently aparasitaemic individuals in Cote d'Ivoire: evidence for a complex and heterogeneous population. Trop Med Int Health 5: 786-793.

9. Ilboudo H, Jamonneau V, Camara M, Camara O, Dama E, et al. (2011) Diversity of response to Trypanosoma brucei gambiense infections in the Forecariah mangrove focus (Guinea): perspectives for a better control of sleeping sickness. Microbes and Infection 13: 943-952.

10. Hanotte O, Ronin Y, Agaba M, Nilsson P, Gelhaus A, et al. (2003) Mapping of quantitative trait loci controlling trypanotolerance in a cross of tolerant West African N'Dama and susceptible East African Boran cattle. Proc Natl Acad Sci U S A 100: 7443-7448.

11. Iraqi F, Clapcott SJ, Kumari P, Haley CS, Kemp SJ, et al. (2000) Fine mapping of trypanosomiasis resistance loci in murine advanced intercross lines. Mamm Genome 11: 645-648.

12. H3Africa C (2014) Research capacity. Enabling the genomic revolution in Africa. Science 344: 1346-1348.

13. Courtin D, Argiro L, Jamonneau V, N'Dri L, N'Guessan P, et al. (2006) Interest of tumor necrosis factor-alpha -308 G/A and interleukin-10 -592 C/A polymorphisms in human African trypanosomiasis. Infect Genet Evol 6: 123-129.

14. Courtin D, Berthier D, Thevenon S, Dayo GK, Garcia A, et al. (2008) Host genetics in African trypanosomiasis. Infect Genet Evol 8: 229-238.

15. Courtin D, Milet J, Jamonneau V, Yeminanga CS, Kumeso VK, et al. (2007) Association between human African trypanosomiasis and the IL6 gene in a Congolese population. Infect Genet Evol 7: 60-68.

16. Courtin D, Milet J, Sabbagh A, Massaro JD, Castelli EC, et al. (2013) HLA-G 3' UTR-2 haplotype is associated with Human African trypanosomiasis susceptibility. Infect Genet Evol 17: 1-7.

17. Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Jannin JG (2012) The Human African trypanosomiasis specimen biobank: a necessary tool to support research of new diagnostics. PLoS Negl Trop Dis 6: e1571.

18. Cattand P, Miezan BT, de Raadt P (1988) Human African trypanosomiasis: use of double centrifugation of cerebrospinal fluid to detect trypanosomes. Bull World Health Organ 66: 83-86.

19. Lumsden WH, Kimber CD, Evans DA, Doig SJ (1979) Trypanosoma brucei: Miniature anion-exchange centrifugation technique for detection of low parasitaemias: Adaptation for field use. Trans R Soc Trop Med Hyg 73: 312-317.

20. Miezan TW, Meda HA, Doua F, Dje NN, Lejon V, et al. (2000) Single centrifugation of cerebrospinal fluid in a sealed pasteur pipette for simple, rapid and sensitive detection of trypanosomes. Trans R Soc Trop Med Hyg 94: 293.

21. Woo PT (1970) The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis. Acta Trop 27: 384-386.

22. Magnus E, Vervoort T, Van Meirvenne N (1978) A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of *T. b. gambiense* trypanosomiasis. Ann Soc Belg Med Trop 58: 169-176.

23. Jamonneau V, Bucheton B, Kabore J, Ilboudo H, Camara O, et al. (2010) Revisiting the immune trypanolysis test to optimise epidemiological surveillance and control of sleeping sickness in West Africa. PLoS Negl Trop Dis 4: e917.

24. Florez-Vargas O, Bramhall M, Noyes H, Cruickshank S, Stevens R, et al. (2014) The quality of methods reporting in parasitology experiments. PLoS One 9: e101131.